Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores

被引：105
作者：
Lip, G. Y. H. [1 ,2 ]
Lane, D. A. [1 ,2 ]
机构：
[1] Univ Birmingham, Inst Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England
[2] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2016年 / 14卷 / 09期
关键词：
STROKE PREVENTION; WARFARIN; ANTICOAGULATION;
D O I：
10.1111/jth.13386
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1711 / 1714
页数：4
相关论文
共 20 条
  • [1] A New Risk Scheme to Predict Warfarin-Associated Hemorrhage The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
    Fang, Margaret C.
    Go, Alan S.
    Chang, Yuchiao
    Borowsky, Leila H.
    Pomernacki, Niela K.
    Udaltsova, Natalia
    Singer, Daniel E.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (04) : 395 - 401
  • [2] Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists
    Focks, J. Jaspers
    van Vugt, S. P. G.
    Albers-Akkers, M. T. H.
    Lamfers, E. J. P.
    Bloem-de Vries, L. M.
    Verheugt, F. W. A.
    Brouwer, M. A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (09) : 1715 - 1724
  • [3] Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation A Report From the Swedish Atrial Fibrillation Cohort Study
    Friberg, Leif
    Rosenqvist, Marten
    Lip, Gregory Y. H.
    [J]. CIRCULATION, 2012, 125 (19) : 2298 - +
  • [4] The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
    Hijazi, Ziad
    Oldgren, Jonas
    Lindback, Johan
    Alexander, John H.
    Connolly, Stuart J.
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Held, Claes
    Hylek, Elaine M.
    Lopes, Renato D.
    Siegbahn, Agneta
    Yusuf, Salim
    Granger, Christopher B.
    Wallentin, Lars
    [J]. LANCET, 2016, 387 (10035) : 2302 - 2311
  • [5] Biomarkers in atrial fibrillation: a clinical review
    Hijazi, Ziad
    Oldgren, Jonas
    Siegbahn, Agneta
    Granger, Christopher B.
    Wallentin, Lars
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 (20) : 1475 - +
  • [6] Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation
    LaHaye, Stephen
    Regpala, Steffi
    Lacombe, Shawn
    Sharma, Mukul
    Gibbens, Sabra
    Ball, David
    Francis, Kori
    [J]. THROMBOSIS AND HAEMOSTASIS, 2014, 111 (03) : 465 - 473
  • [7] Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation
    Lane, Deirdre A.
    Lip, Gregory Y. H.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2014, 111 (03) : 381 - 383
  • [8] Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation
    Lip, Gregory Y. H.
    Lane, Deirdre
    Van Walraven, Carl
    Hart, Robert G.
    [J]. STROKE, 2006, 37 (09) : 2294 - 2300
  • [9] Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (46) : 3265 - 3267
  • [10] Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score
    Lip, Gregory Y. H.
    Skjoth, Flemming
    Nielsen, Peter B.
    Larsen, Torben Bjerregaard
    [J]. THROMBOSIS AND HAEMOSTASIS, 2015, 114 (04) : 826 - 834
12